Phytohemagglutin in (PHA)-induced IL-2 production in vitro by peripheral blood mononuclear cells (PBMC)and lamina propria mononuclear cells (LPMC)from patients with active UC (n=24, n=8, respectively) was significantly less than that in controls (n=13, n=8, respectively) and inactive patients (n=ll). In contrast, PBMCfrom inactive disease showed no significant difference whencompared with the controls. Depressed IL-2 production in active UCwas not reversed by the addition of anti-CD3 monoclonal antibody plus phorbol myristate acetate (PMA), but was largely reversed by adding calcium ionophore plus PMA. Using a fluorescent Ca2+ probe fura-2, we found that after PHAstimulation LPMCfrom patients with active UCshowed a lower magnitude of rise in intracellular free calcium concentration ([Ca2+]j) than control cells. These results suggest that impaired PHA-induced IL-2 production in active UCmay be related to some alterations of the early signaling events that cause elevation of the [Ca2+]j. (Internal Medicine 33: 739-744, 1994) 
Introduction
Previous studies have shown that interleukin-2 (IL-2) production is decreased in vitro in patients with active ulcerative colitis (UC) compared with controls (1, 2) . IL-2 is a cytokine produced by T cells in response to mitogen or antigen stimulation, and it plays a crucial role in the regulation of immune responses (3, 4) . Thus, deficient IL-2 activity can lead to immunologic abnormalities in UCpatients, such as the disruption of normal T cell proliferation and differentiation. T cell activation during antigen recognition is mediated by at least two synergistic intracellular signals; i.e., an increase in the intracellular free calcium concentration ([Ca ]{) and the activation of protein kinase C (PKC) (5, 6) . However, the combination of a calcium ionophore and a PKCactivator such as phorbol myristate acetate (PMA)bypasses the requirement for an antigen-induced signal at the onset of T cell activation (7) . The purpose of this study was to investigate the IL-2 activity generated in response to phytohemagglutinin (PHA) or PMA combined with anti-CD3 monoclonal antibody (mAb) or calcium ionophore using peripheral blood mononuclearcells (PBMC)and lamina propria mononuclear cells (LPMC) obtained from patients with UCWealso evaluated intracellular Ca2+mobilization under these conditions in an attempt to clarify the mechanism of the decreased PHA-induced IL-2 production in active UC.
Materials and Methods

Subjects
Biopsy specimens (n=8) and peripheral blood (active disease: n=24, inactive disease: n=ll) were obtained from 24 patients with UC who were undergoing diagnostic or follow-up colonoscopy at Nagoya University Hospital. The group included 14 males and 10 females, ranging in age from 19 to 59 years (mean age; 36.5±5.8 years). The diagnosis of UC was confirmed by clinical, endoscopic, radiologic, and histological criteria (8, 9) . Fourteen patients had total colitis and 10 had leftsided colitis. The duration of disease ranged from 1 month to 12
years. At the time of the study, 9 patients were receiving corticosteroids alone, 3 were on sulfasalazine alone, and 12
were being treated with both agents. None of them were receiving calcium channel blockers or cyclosporin A. To isolate control non-UC LPMC, large bowel specimens were collected from 8 patients undergoing colectomy for colon cancer (n=6) or colonic diverticular disease (n=2). Five of these patients were menand three were women,ranging from 41 to 68 years of age (mean age; 58.6±6.5 years colonic mucosae obtained by a biopsy forceps from surgical specimenswere washedfree of mucuswith HBSS, after which the tissues were stirred for 30 minutes in HBSSwith 1 mM dithiothreitol and then twice for 90 min with 1 mMethylenediamine tetraacetate to remove epithelial cells. The tissues were then gently stirred for 12 hours at 37°C in HBSSwith 0.02% collagenase (Worthington Diagnostic Systems Inc., Freehold, NJ) and 0.01% deoxyribonuclease (Worthington). Subsequently, the cell suspension was filtered through nylon mesh (100 jam), and the resultant LPMCwere purified on a Ficoll-Hypaque gradient, washed twice, then resuspended in the culture medium.
Induction of interleukin-2 production by peripheral blood and lamina propria mononuclearcells For the induction of IL-2 production, cells were cultured at 1x106/ml in a humidified atmosphere of5% CO2' 95% airfor48 hours at 37°C in the culture mediumunder the following conditions: (a) with 10 Jig/ml PHA (Difco Laboratories, Detroit, Mich.) (12) , and (b) with 40 ng/ml phorbol-12-myristate-13-acetate (PMA; Sigma Chemical, St. Louis, Mo.) plus 1: 100 dilution of anti-CD3 mAb OKT3(Ortho Diagnostic System Inc., Raritan, NJ). This particular combination of PMAand OKT3is known to induce IL-2 messengerRNA in T lymphocytes (13) . In addition, (c) a combination of 40 ng/ml PMAand calcium ionophore A23 1 87 (Calbiochem, La Jolla, CA) at 250 nMwas used. The optimal dosages of these agents and the appropriate incubation period for IL-2 production were determined by the previous study (2) . At the end of culture, cells were pelleted by centrifugation and the supernatants were collected, sterilized by nitration (0.45 |im), and stored at -70°C until assayed for IL-2 activity.
Assay of interleukin-2 activity
TheIL-2 activity of the culture supernatants wasmeasured by bioassay using an IL-2-dependent cytotoxic mouse T-cell line (CTL-N, kindly provided by Dr. Fiocchi, Case Western
Reserve University, Cleveland, OH). Serial dilutions of culture supernatant were added to CTL-N cells in roundbottomed microtiter plates (lxlO4/well) and incubated for 1 8 hours. The cultures were then pulsed for 6 hours with 0.5 jiCi of 3H-thymidine (New England Nuclear, Boston, MA)and harvested onto glass fiber filters, after which the radioactivity was determined using a liquid scintillation counter (Beckman, Palo Alto, CA). One unit of IL-2 activity was defined as the inverse of the sample dilution yielding the same numberof counts per minute response of a standard recombinant IL-2 (kindly provided by Takeda Chemical Ind., Osaka, Japan), as determined by probit analysis (14) .
Measurement of the intracellular
Ca2+ responses usingfura-2 Intracellular calcium responses were assessed by monitoring the fluorescence of mononuclear cells loaded with the calcium indicator fura-2 (15, 16) . For the dye loading, LPMC (5xl06/ml) isolated from active UCpatients and controls were incubated with fura-2 acetoxymethyl ester (4 |LiM, Dojin Chemical Co., Kumamoto, Japan) in Ca2+/Mg2+-free PBS for 30 min at 37°C. The cells were then washedtwice and resuspended at lxlO6/ml in Ca2+/Mg2+-free PBS containing 10 mMHEPES, 0.5% FCS, and 10 mMglucose (pH 7.4). Aliquots of cells were dispensed into quartz cuvettes and the external Ca2+concentra-tion was adjusted to 1 mMwith CaCl2. Changes in fluorescence were monitored using a fluorescence spectrophotometer (CAF-1 00, Japan Spectroscopy Co. Ltd.) after stimulation with either PHA (10 |ig/ml), OKT3 (diluted 1 : 100) plus PMA (40 ng/ml), or ionomycin (250 nM, Sigma Chemical Co., St. Louis) plus PMA.During measurement, the temperature of the cell suspension was kept at 37°C and the suspension was continuously stirred. The excitation and emission wave-lengths were 340/ 380 and 510 nm, respectively. Changes of [Ca2+]i were expressed as the ratio of the two fluorescence readings.
Statistical analysis Statistical analysis was performed using Kruskal-Wallis test followed by Wilcoxon's rank sum test. Probability values less than 0.05 were considered to indicate significance. All data were expressedas the mean±SEM.
Results
Interleukin-2 production by PBMC
In healthy volunteers, PHA-induced IL-2 production by
PBMCaveraged 35.6±5.5 U/ml. The values from UC patients IL-2 Production in Ulcerative Colitis were 3.9±0.8 U/ml for active disease and 33.0+19.4 U/ml for inactive disease (Fig. 1) . PHA-induced IL-2 production by PBMCfrom patients with UCwas significantly depressed in active phase, but not in quiescent disease whencompared with controls (p<0.0 1 ). In contrast, IL-2 production by PBMCstimulated with A23 1 87 plus PMAshowed no significant difference between the controls (285.7+57.6 U/ml) and active UCpatients (258.4+88.6 U/ml) (Fig. 2) .
Interleukin-2 production by LPMC Changes of intracellular Ca2+ levels induced by PHA, 0KT3 plus PMAor a calcium ionophore After LPMCfrom controls and patients with active UCwere loaded with fura-2 acetoxymethyl ester, the cells were stimulated with PHA, OKT3plus PMA, or ionomycin plus PMA. In control LPMC,PHAinduced an immediate increase in [Ca2+]j, and OKT3plus PMAor the combination of ionomycin plus PMAcaused further elevation of [Ca2+]i, which reached a maximal value after two minutes (Fig. 4A, B, C) . In contrast, in LPMCfrom patients with active UC, PHAor the combination of OKT3 plus PMAtriggered smaller increases in [Ca2+]i than in controls. On the other hand, ionomycin plus PMAinduced a long-lasting increase in [Ca2+]i which was comparable to that in controls (Fig. 4D, E, F) . The magnitude of intracellular Ca2+ response to PHAin control was significantly larger than that observed in patients with active UC (Fig. 5) .
Discussion
This study showed that PHA-induced IL-2 production by LPMCand PBMCwas reduced in patients with active UC. Previous investigations using PBMCand LPMCisolated from surgical specimens have also indicated the impairment of mitogen-induced IL-2 production in UC patients (2, 17) . The precise mechanism of this abnormality, which is also recognized in some autoimmune diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (18, 19) , is still unclear. Several investigators have indicated that IL-2 hyposecretion under these conditions may be due to the refractoriness of T cells that have been continuously activated in vivo (20, 21) . Increased in vivo activation of T cells might result in defective IL-2 production in response to further stimulation in vitro. Another possibility has been suggested that an intrinsic defect of IL-2 production might reside in the dysfunction of SLE lymphocytes (22, 23) or accessory cells (24). In patients with SLEthere were severe defects in both IL-1 and IL-2 production by PBMC.It was reported that low IL-2 production in SLE could not be restored to normal by adding purified IL-1 in some patients, nor by removal of monocytes, and speculated that there existed possible multifactorial mechanisms (25).
On the other hand, the impaired ability of UCT cells to produce IL-2 may be related to one or more abnormalities in In the present study, we explored whether normalization of IL-2 production could occur in vitro whenseveral activation agents were applied to stimulate T cells from active UCpatients. In particular, we focused on the response mediated via the CD3/TCRcomplex and demonstrated that depressed IL-2 production capacity ofLPMCfrom active UCpatients could be restored by PMA in combination with calcium ionophore A23187, but not by PMA combined with an anti-CD3 mAb. T cell activation by ligands that interact with the CD3/TCR complex (e.g., anti-CD3 mAb) requires the presence of monocytes. Although PHAinduces polyphosphoinositide turnover (29), PKC activation is also necessary for optimal T cell activation and cytokine production. Because PMAis considered as a natural analogue of diacylglycerol which binds to and activates PKC, PMAcan be used to substitute for this function ofmonocytes and bypass the signal transduction pathway when administered in combination with a calcium ionophore. Additionally, unlike with SLE, there is no evidence of decreased production of IL-1 in patients with UC(30). Thus, these results suggest that the mechanismof PHA-inducedin vitro IL-2 hyposecretion by PBMCand LPMCfrom UCpatients might be related to an alteration of the early events during signal transduction through the CD3/TCRcomplex on T cells. Next, we examined the changes in intracellular Ca2+ levels induced by PHA, OKT3 plus PMA, or ionomycin plus PMA. The intracellular Ca2+ response to PHAwas reduced in amplitude in LPMCfrom most of the active UCpatients. In contrast, the response to the calcium ionophore was conserved in these patients. Defective calcium response was reported not only in SLE but also in B-chronic lymphocytic leukemia cells, and in the later condition it was speculated that defective signal transduction was related to the interruption of the phosphoinositide pathway or an altered pattern of protein tyrosine phosphorylation (3 1 ). Activation ofPKC alone is reported to be insufficient to induce T cell activation, and an additional signal such as a long-lasting increase in [Ca2+]i is necessary for optimal T cell activation and for cytokine production (32). Taken together, these results suggest that the reduced Ca2+ response parallels the defective PHA-induced IL-2 secretion in active UC. Further investigations at the single cell level or using biochemical measurements is required to clarify the mechanism(s) of this impaired Ca2+ response in active UC.
In summary, our findings suggested that the average Ca2+ response to PHAwas altered in LPMCfrom patients with active UC and that this change may be related to IL-2 hyposecretion invitro.
